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Towards a total synthesis of guanacastepene A: construction of
fully functionalized AB and BC ring segments
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Abstract—Studies directed towards the total synthesis of the diterpene antibiotic, guanacastepene A, of current interest and
displaying promising biological activity against drug-resistant pathogens, has led to the acquisition of fully functionalized AB and
BC ring segments of the natural product. 
Isolation and structure determination of a novel diter-
pene, guanacastepene A 1, from an unidentified endo-
phytic fungus growing on the tree Daphnopsis
americana has been recently reported by Clardy et al.1a
and shown to exhibit impressive activity against methi-
cillin-resistant Staphylococcus aureus and vancomycin
resistant Enterococcus faecium. In further biological
studies 1 exhibited moderate activity against Gram-pos-
itive bacteria, poor activity against Gram-negative bac-
teria and hemolytic activity against human RBC.1b
While these latter attributes undermine the therapeuti-
cal potential of 1, its analogues may offer good chances
of harnessing the antibiotic activity of this system
against drug-resistant pathogens. Thus, an intensive
world-wide quest for synthetic and naturally occurring
analogues of 1 is on. More recently, several additional
guanacastepenes B–O have been isolated from the same
fungus but among them only guanacastepene I 2 shows
moderate biological activity.1c A total synthesis of gua-
nacastepene A 1 has not been accomplished so far
although this target has attracted widespread attention
and during the past year several model studies have
been reported.2–6
Considering the synthetic challenge posed by the 5, 7,
6-fused tricarbocyclic framework of 1, replete with
complex stereochemical and functionalization pattern,
initial attention has been focussed on the hydroazulenic
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AB-ring substructure present in it. Preliminary reports
from the research groups of Snider,2a Danishefsky2b,c
and Magnus2d have outlined strategies leading to the
AB ring models 3, 4 and 5, respectively. Our approach
to 1 has led to 6.3 An approach towards the BC ring
model of guanacastepene A 1 has also been described.4
The AB ring hydroazulenic models 3–6 reported so far
en route to 1 are well short of the requisite functional-
ization required in the natural product and no solution
is available thus far for generating the sensitive ,-
unsaturated aldehyde–allylic alcohol functionality
present in ring C of guanacastepene A 1.2–6 We report
here the acquisition of the AB and BC ring segments 7
and 8 of 1, with full complement of functionality and
stereochemistry present in the natural product. The
access to bicyclic structures 7 and 8 delineated here
should pave the way for the total synthesis of 1 and
enable access to a range of model compounds and
analogues for biological screening.
We have recently described the transformation of the
readily available tricyclic enone 9 into cyclopentenone
10 through a short sequence.3 Sodium borohydride
reduction of 10 led to a mixture of allylic alcohols 11
(-OH) and 12 (-OH) in an 85:15 ratio (Scheme 1).7
Directed epoxidation8 of allylic alcohol 12 led to the
epoxy–alcohol 13 as a single diastereomer and was
further converted to the acetate 14.7 Ring-closure
metathesis in 14 in the presence of Grubbs’ catalyst9
delivered the bicyclic hydroazulene derivative 15 and
the cycloheptene double bond was reduced to give 16.
TMSOTf-mediated10 opening of the epoxide ring in 16
proceeded as planned to give, after the removal of the
TMS protecting group, allylic alcohol 17 (Scheme 1).7
Oxidation of the allylic hydroxy group in 17 delivered
the desired AB ring segment 7 of guanacastepene A 1
with exact functionality and stereochemistry (Scheme
1).11 Although, the reduction of 10 was non stereoselec-
tive and only the minor isomer 12 was the required one,
the redeeming feature was that the unwanted isomer 11
could be recycled through oxidation to 10.
Attention was next turned towards the BC ring frag-
ment 8 of 1. Sequential alkylation of cycloheptanone 18
with methyl iodide and tris-isopropyl protected 5-iodo-
1-pentyne furnished 19 (Scheme 2). Removal of the
TIPS protective group in 19 and titration of the result-
ing acetylenic ketone 20 with a solution of sodium
naphthalenide resulted in intramolecular reductive
cyclization to furnish a separable mixture (40:60) of
cis-21 and trans-bicyclic alcohol 22 (Scheme 2).12–14
Both the allylic alcohols 21 and 22 underwent a smooth
oxidative transposition reaction in the presence of PCC
to furnish 23 having the unsaturated aldehyde function-
ality present in guanacastepene A 1. To complete the
full complement of functionality in the C ring of the
natural product, the trans-allylic alcohol 22 was sub-
jected to catalytic selenium dioxide oxidation to furnish
a single crystalline diol 24 (Scheme 2).7 X-Ray single-
crystal structure15 (Fig. 1) determination on 24 confi-
rmed the stereoselective nature of the allylic
hydroxylation reaction to install the correct relative
stereochemistry at the angular methyl group and the
secondary hydroxyl group. Selective acetylation of the
hydroxyl group in 24 to give 25 and PCC mediated
oxidative allylic transposition yielded the BC ring seg-
ment 8 of guanacastepene A 1 in a short sequence from
commercially available cycloheptanone 18 (Scheme 2).
Scheme 1. Reagents and conditions : (i) NaBH4, CeCl3, MeOH 90%, 11:12=85:15; (ii) m-CPBA, CH2Cl2, 0–15°C, 65%; (iii) Ac2O,
DMAP, CH2Cl2, 0°C–rt, 90%; (iv) Grubbs’ catalyst, C6H6, , 5 h, 92%; (v) H2, 10% Pd/C, EtOAc, quant.; (vi) (a) TMSOTf,
DMAP, Py, rt, 2 days (b) 5% HCl, THF, 0°C, 75% for the two steps; (vii) MnO2, CH2Cl2, rt, 5 h, 98%.
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Scheme 2. Reagents and conditions : (i) (a) LDA, HMPA, −78°C, 20 min, (b) CH3I, −78°C–rt, 62%; (ii) (a) KH, 0°C, 3 h, (b)
I(CH2)3CCTIPS, 0°C–rt, 18 h, 66%; (iii) TBAF, THF, rt, quant.; (iv) C10H8, Na, THF, rt, 30% (21/22:40/60); (v) PCC, CH2Cl2,
0°C–rt, 4 h, 90%; (vi) SeO2,
tBuOOH, salicylic acid, CH2Cl2, rt, 24 h, 40%; (vii) Ac2O, DMAP, CH2Cl2, 0°C–rt, 3 h, quant.; (viii)
PCC, CH2Cl2, 0°C–rt, 8 h, 80%.
Figure 1. ORTEP diagram of 24.
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